Uremic Toxin–Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome
Authors:
Open Access
- 25 December 2019
- journal article
- review article
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 84 (1) , 2-8
Abstract
Chronic kidney disease (CKD) is a global health problem. CKD patients are at high risk of developing cardiovascular disease (CVD), including coronary artery disease, heart failure and stroke. Several factors invoke a vicious cycle of CKD and CVD, which is referred as to “cardiorenal syndrome”. Among these factors, the compounds retained through loss of renal excretion play a pathological role in causing atherosclerosis and CVD. These compounds have been broadly classified as uremic toxins because of their accumulation with declining renal function and cytotoxicity. The major uremic toxins contributing to CVD are asymmetric dimethylarginine (ADMA), advanced glycation endproducts (AGE), and trimethyl amine N-oxide (TMAO). ADMA is linked to CVD through regulation of nitric oxide, reactive oxygen species, and renal anemia. AGE not only directly accumulates in the heart and kidney, but interacts with the receptor for AGE (RAGE), leading to cell damage in CVD. TMAO correlates with a high prevalence of CVD and promotes organ fibrosis by itself. The levels of these and other uremic toxins rise with worsening CKD, inducing multiplicative damage in the heart and kidney. Therefore, a better understanding of uremic toxins has great clinical importance for preventing cardiorenal syndrome. This review highlights the molecular mechanism by which these uremic toxins are implicated in CVD and suggests the possible mutual relationship between them.Keywords
This publication has 71 references indexed in Scilit:
- Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosisNature Medicine, 2013
- Effects of Sevelamer on HbA1c, Inflammation, and Advanced Glycation End Products in Diabetic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2012
- Gut flora metabolism of phosphatidylcholine promotes cardiovascular diseaseNature, 2011
- Early Sympathetic Activation in the Initial Clinical Stages of Chronic Renal FailureHypertension, 2011
- RAGE Modulates Hypoxia/Reoxygenation Injury in Adult Murine Cardiomyocytes via JNK and GSK-3β Signaling PathwaysPLOS ONE, 2010
- ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxideAmerican Journal of Physiology-Renal Physiology, 2009
- Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42Journal of Biological Chemistry, 2008
- Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in DiabetesDiabetes, 2008
- Coronary Artery Calcification, ADMA, and Insulin Resistance in CKD PatientsClinical Journal of the American Society of Nephrology, 2008
- Pegaptanib 1-Year Systemic Safety Results from a Safety–Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular DegenerationOphthalmology, 2007